Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased due to efforts to promote sales of generic drugs related to renal and dialysis care, among other factors. However, operating income and ordinary income decreased because the cost-of-sales ratio rose as raw material and labor costs increased, and research and development expenses related to DMX-200 increased. In the previous fiscal year, the company recorded ¥8,744 million as an extraordinary loss for the provision for litigation-related losses.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥62,307 million (YoY +2.9%) |
| Operating profit | ¥2,639 million (YoY -36.1%) |
| Ordinary income | ¥2,349 million (YoY -37.9%) |
| Profit attributable to owners of the parent | ¥2,011 million |
| Net income per share | ¥235.63 |
| Operating Margin | 4.2％ |
| Equity ratio | End of the current fiscal period 38.8％ / End of previous period 40.4％ |
| Total assets | ¥90,323 million |
| Net assets | ¥35,057 million |
| Cash flows from operating activities | ¥-6,224 million |
| Cash flows from investing activities | ¥-1,515 million |
| Cash flows from financing activities | ¥6,321 million |
| Cash and cash equivalents at end of period | ¥4,846 million |
| Full-year earnings forecast | Net Sales ¥63,200 million (YoY +1.4%) / Operating profit ¥2,000 million (YoY -24.2%) / Ordinary income ¥1,400 million (YoY -40.4%) / Net income for the current fiscal year ¥1,300 million (YoY -35.4%) |
| Annual Dividend Forecast | ¥82 → ¥90 |
| Payout ratio | 38.2% (fiscal year ending March 2026), 59.1% (forecast for fiscal year ending March 2027) |
| Depreciation and amortization | ¥2,618 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥118 million / Extraordinary loss Loss on sale of investment securities ¥26 million, Impairment loss on investment securities ¥1 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes Yes / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Held (for media representatives) |
| Issued Shares at Period-End | 9,451,169 Shares |
| Treasury Shares at Period-End | 914,118 Shares |
| Factors Behind Changes in Business Performance | Net sales increased due to efforts to promote sales of generic drugs related to renal and dialysis care, among other factors. However, operating income and ordinary income decreased because the cost-of-sales ratio rose as raw material and labor costs increased, and research and development expenses related to DMX-200 increased. In the previous fiscal year, the company recorded ¥8,744 million as an extraordinary loss for the provision for litigation-related losses. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to efforts to promote sales of generic drugs related to renal and dialysis care, among other factors. However, operating income decreased because the cost-of-sales ratio rose more than expected as raw material and labor costs increased, and research and development expenses rose as research and development activities related to DMX-200 progressed. In the previous fiscal year, the company recorded ¥8,744 million as an extraordinary loss for the provision for litigation-related losses.